New Lilly RNAi Drug Development Collaboration

Lilly announced a new collaboration with Dicerna for the development and commercialization of RNAi therapeutics treating cardio-metabolic disease, neurodegeneration, and pain. It remains unclear if or how this collaboration will impact Lilly’s diabetes business unit. Below, FENIX provides general thoughts on RNAi treatments as well as potential diabetes-related targets that Lilly/Dicerna could be pursuing.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.